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Intracellular organelles do not, as thought for a long time,
act in isolation but are dynamically tethered together by entire
machines responsible for interorganelle trafficking and posi-
tioning. Among the proteins responsible for tethering is the
family of VAMP-associated proteins (VAPs) that appear in all
eukaryotes and are localized primarily in the endoplasmic
reticulum. The major functional role of VAPs is to tether the
endoplasmic reticulum with different organelles and regulate
lipid metabolism and transport. VAPs have gained increasing
attention because of their role in human pathology where
they contribute to infections by viruses and bacteria and
participate in neurodegeneration. In this review, we discuss
the structure, evolution, and functions of VAPs, focusing
more specifically on VAP-B for its relationship with amyo-
trophic lateral sclerosis and other neurodegenerative diseases.
The eukaryotic cell has been thought of for a long time as a
sort of container of several other smaller containers, the or-
ganelles, separated from each other by organellar membranes
and without direct physical links. This view has been
completely revolutionized by electron microscopy evidence
that has first raised and then proven that organelles might be
talking to each other through connectors mostly constituted
by proteins or protein complexes that form fixed or transient
molecular tethers (for comprehensive reviews, refer for
instance the study by Eisenberg-Bord et al., 2016 (1), and
Henne et al., 2016 (2), and references within).
The discovery of tethers has offered a new perspective on
the functioning of a cell and proposed a new route for regu-
lation and trafficking between organelles. The list of proteins
reported to be involved in tethering has increasingly been
expanding. To date, proteins that act as tethers between the
endoplasmic reticulum (ER) and the plasma membrane,
mitochondria, and endosomes/lysosomes have been identified
in several different organisms (1). It is thus well accepted that
many, if not all organelles, are physically tethered, providing a
description of the cell interior in which organelles are spatially
organized and functionally interconnected in a static and/or
dynamic fashion.
Tethering can involve proteins that physically bridge two or-
ganelles attaching them to each other, correctly positioning or-
ganelles for division or inheritance (1, 3). Other tethers also have
specific functions, such as playing a role in the transfer of small
molecules (e.g., lipids, calcium) in a nonvesicular manner. Recent
studies have started to uncover the molecular mechanisms of
tethering to understand their spatial, temporal, and functional
organization. We are beginning to understand that each contact
site is a functional microenvironment based on the concerted
activity of distinct types of tether and nontether components.
In this review, we want to zoom in on a specific family of
tethering proteins, the VAMP-associated proteins (VAPs), where
VAMP stands for vesicle-associated membrane protein. Discov-
ered in the last decade of last century, only recently has enough
interest been paid to these proteins both because they constitute
one of the best described tethering systems and because of their
association with the disease. We focus on these proteins because
of their important role in neurodegeneration. They constitute a
family of integralmembrane proteins that tether the ER toplasma
membrane, mitochondria, endosomes, and the Golgi apparatus.
Wewill discuss here the architecture, evolution, interactions, and
the multiple functional roles of VAPs.We relate these features to
the importance of VAPs in disease, both in viral and bacterial
infections, and in neurodegeneration including amyotrophic
lateral sclerosis (ALS), frontotemporal dementia, Alzheimer’s
disease (AD), and Parkinson’s disease (PD). We have chosen not
to include links of VAPs to cancer not for the lack of interest but
to focus the review on two aspects, infectious and neurodegen-
erative diseases, which have only relatively recently been linked
together (4–8). The role of VAPs in cancer is in its infancy and
possibly still indirect (9).
The VAP family
The first VAP was identified in Aplysia californica by a yeast
two-hybrid screen using as a bait the v-SNARE VAMP (also
known as synaptobrevin), a protein required for synaptic-
vesicle fusion. From this work, the protein was named
“VAP” for its association with vesicles or “VAP33”, as the
Aplysia protein migrated as a 33-kDa protein on SDS-PAGE
(10–14). VAPs are found in all eukaryotic organisms where
they play important functions in membrane trafficking (10),
neurotransmitter release, and lipid transport (15). They also* For correspondence: Annalisa Pastore, annalisa.pastore@crick.ac.uk.
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participate in the unfolded protein response machine, an ER
reaction that suppresses accumulation of misfolded proteins to
maintain cell viability and function (16).
VAPs are ubiquitously expressed, but their expression levels
depend on cell and tissue types (17–19). In addition to their
main localization in the ER (19–22), they have also been found
in other intracellular membranes, including the Golgi, the ER–
Golgi intermediate compartment (11, 12), recycling endo-
somes (14, 23), tight and neuromuscular junctions (16), and
plasma membrane (15).
Amino acid sequences of VAPs are highly conserved from
yeast to mammals with the human protein sharing 99%
identity with mouse and 35% with yeast (17–19, 24, 25).
Vertebrates have two closely related VAP genes, VAP-A and
VAP-B. VAP-A and VAP-B share high (typically, ca., 63%)
amino acid sequence identity. An alternative spliced isoform of
VAP-B comprised of the N-terminal 70 with additional 29
amino acids was also identified and named VAP-C (18).
The three-dimensional structure of VAPs
The architecture of VAPs is modular and composed of three
conserved domains (Fig. 1A): an N-terminal major sperm pro-
tein (MSP) domain (residues 1–126 of humanVAP-B), followed
by a central amphipathic domain that is predicted to comprise a
coiled-coil domain (residues 165–202), and a C-terminal hy-
drophobic transmembrane domain (residues 220–243). The
MSP is a nematode protein homologous to VAPs that shares
with these the same domain architecture and evinces a high
degree of amino acid sequence similarity in the N-terminal
domain (48% identity). The MSP domain has an immunoglob-
ulin (Ig) fold (26), a structure found in very diverse protein
families throughout the living systems. Ig-like domains are
involved in a variety of functions, including cell–cell recogni-
tion, cell–surface receptors,muscle structure, and, of course, the
immune system. As in all Ig folds, the domain consists of a
β-sandwich assembled by two β-sheets packed face-to-face and
enclosing the hydrophobic core of the protein (Fig. 1B,
Supplemental Data S1). The nearly ellipsoidal shape of the
domainmeasures approximately 15Å×20Å×45Å.A stretch of
16 amino acids in theMSPdomain, the so-calledVAPconsensus
sequence, is particularly conserved (21, 27). The structures of
theMSPdomains of VAP-A andVAP-B proteins are available in
the Protein Data Bank (PDB) (Table 1).
The recombinant isolated MSP domain is a monomer in the
solution, but it may contribute to dimer formation of the full-
length protein together with other regions of the protein
(28, 29). The coiled-coil domain that follows the MSP is a
motif often found in VAMP and SNARE proteins and in
several other proteins implicated in vesicular transport (18).
These proteins share clear sequence homology that goes
beyond the presence of leucine-zipper heptads (30). The
evolutionary conservation of the SNARE coiled-coil homology
domain has thus suggested that the domain fulfills a similar
function in different membrane fusion proteins. The C-ter-
minal hydrophobic transmembrane domain contains a puta-
tive dimerization motif GxxxG that could favor both
homodimerization and heterodimerization (18, 31).
The peculiarities of the Ig fold of the MSP family
It is worth spending a few words about the MSP domain
because it has some interesting peculiarities. The Ig domain of
VAPs is at the sequence level homologous to the nematode
MSP, and similar, at a structural but not at the sequence level,
to the bacterial pilus PapD chaperone. In nematodes, the MSP
is a small (14 kDa) basic protein encoded by a multigene
family of up to 28 members and prone to dimerization (32).
Locomotion in amoeboid nematode sperm cells (which instead
of swimming like typical sperm crawl like amoebae) is pro-
duced by bundling of filaments formed by MSP, constructed
from two helical subfilaments that coil around each other and
are arranged into long, branching, fiber complexes. PapD is a
periplasmic chaperone that assists the assembly of adhesive pili
in gram-negative bacteria. Its function is to bind, stabilize,
and cap the different filamental subunits until they are
assembled into the pilus. The chaperone provides the seventh
missing strand necessary to complete the Ig fold of the pilus
subunits.
Despite their completely different origin and functions, the
Ig folds of MSP, VAP, and PapD are remarkably similar and
can be classified as S-type (for switching type) as compared
with the C-, V-, and I-types (Fig. 2, Supplemental Data S2).
The S-subfamily has several features that make it distinct from
other Ig folds despite a general closeness to the I-type sub-
family (33, 34). The β-sheets in S-type Ig domains have two
switching points. Strand 1 begins in one of the sheets but
transfers to the other, through an S-shaped bulge centered, in
MSP and VAP on a proline (P12 in VAP-B numbering) in an
unusual cis-conformation. In PapD, the switching is shifted
Figure 1. The structure of VAPs. A, schematic representation of the
domain architecture along the sequence. B, three-dimensional structure of
VAP-B (PDB code: 3ikk) as a stereo view. The two prolines indicated (P12
and P56) are the points at which the strands switch from one sheet to the
other as described in section “The peculiarities of the Ig-fold of the MSP
family.” The region shown in orange (residues 42–57) shows the VAP
consensus sequence. PDB, Protein Data Bank.
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and different. Switching within the first strand occurs also in
the I and V subfamily but does not involve a cis-proline. A
second switching between strands occurs at the C’ strand that
forms another S-shaped bulge centered on P56 (VAP-B
numbering). Another noticeable difference between MSP and
more classical Ig domains is the absence of the buried tryp-
tophan strongly conserved in the V-, C-, and I-Ig subfamilies.
At this position, VAP-B has V44 that packs tightly against the
rest of the hydrophobic core (Fig. S1).
Interesting questions raised by comparison of VAP-B MSP
domain, MSP, and PapD are whether the S-type fold arose
from convergent or divergent evolution from the rest of the Ig
superfamily and whether its specific features are dictated by
function. Although involved in different contexts, all three
proteins have functions that require specific mechanical
properties that might be achieved by this specific variant of the
Ig fold. It may thus be interesting, in the future, to probe the
resistance against unfolding and resilience of the S-type fold
and compare its properties with those of other members of the
Ig family.
Molecular evolution of VAPs
VAP homologs that contain theMSP domain (PFAMnumber
PF00635) and the C-terminal transmembrane helix appear to be
widespread among eukaryotes, with experimentally character-
ized representatives in A. californica (10), Drosophila
Table 1
Summary of the available structures of VAPs
PDB code Protein description Method Resolution
1z9o Rat VAP-A MSP homology domain in complex with the rat
ORP1 FFAT motif
X-ray 1.9 Å
1z9l Rat VAP-A MSP homology domain X-ray 1.7 Å
2cri Mouse MSP domain of VAP-A NMR Not applicable
2rr3 Complex of human VAP-A MSP domain and the OSBP FFAT
motif
NMR Not applicable
2mdk MSP-P56S domain VAP-B in dodecylphosphocholine NMR Not applicable
3ikk Human MSP domain X-ray 2.5 Å
MSP, major sperm protein; PDB, Protein Data Bank.
Figure 2. Similarities and differences within the Ig superfamily. A, schematic representation of the Ig C-, V-, I- and S-fold types. The two distinct sheets of
the β-sandwich are indicated in blue and purple. B, comparison in stereo of the three-dimensional structures of VAP-B (PDB code: 3ikk), MSP (PDB code:
1grw), and PapD (PDB code: 3dpa). Ig, immunoglobulin; PDB, Protein Data Bank.
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melanogaster (35), Saccharomyces cerevisiae (27), Caeno-
rhabditis elegans (32), Arabidopsis thaliana (36), and with pre-
dicted proteins in species such as Plasmodium falciparum
(PF3D7_1439800), Trypanosoma brucei (TbgDal_XI14770),
Naegleria gruberi (NAEGRDRAFT_80113), and Phytophthora
infestans (PITG_02627) (Fig. 3). These examples cover themajor
branches of the eukaryotic tree (16). Most, but not all, of the
homologs also contain a coiled-coil region implicated in
dimerization. Homology between VAPs andMSPs appears clear
from sequence comparison (37) and includes, for example, the
16-aa VAP consensus sequence (27). In contrast, a possible ho-
mology with PapD is not at all clear, as the E-values are insig-
nificant even using sensitive homology detection (38). PapD
proteins do not contain the conserved sequence motif or the C-
terminal transmembrane helix. The origin of the VAP family
therefore appears to be at the root of the eukaryotes, consistent
with the origin of the endomembrane system inwhich they play a
major role.
In humans, VAP-B has, besides VAP-A, three other ho-
mologs, MOSPD1, MOSPD2, and MOSPD3. These proteins
have been identified independently from VAP-A/B but belong
to the same MSP domain containing family. MOSPD1 and
MOSPD3 play a pivotal role in developmental regulation (39),
and MOSPD2 has been linked to membrane tethering (37). As
compared with VAP-A and VAP-B, MOSPD2 has an extra
CRAL–TRIO domain (40), N-terminal to the MSP domain,
whereas MOSPD1 and MOSPD3 have an extra C-terminal
transmembrane helix. The CRAL–TRIO domain is a structural
module with an α/β fold that binds small lipophilic molecules.
These are hosted in a large hydrophobic cavity formed be-
tween a six-strand β-sheet and a cluster of α-helices. Exami-
nation of the SMART database showed that the combination
of the MSP domain with the CRAL–TRIO domain as present
in one nematode MSP and in MOSPD2 is only observed in
metazoa and therefore appears to have evolved later than the
simpler architecture present in VAP-A and VAP-B.
VAPs as molecular tethers and lipid metabolism
proteins
Having discussed the structure and evolution of VAPs, it is
now to consider their functions. A major role of VAPs is that
of tethering the ER with other organelles and/or to regulate
lipid transport and metabolism. The VAP interactome is thus
rich because it reflects the different localizations and the
associated specific functions of these proteins. Overall, the
endogenous VAP-interacting proteins can be divided into two
broad groups: SNARE and FFAT motif–containing proteins
(Table 2). VAP-A, for instance, binds promiscuously several
different SNAREs. This suggests that, rather than being asso-
ciated with the regulation of a specific protein, VAP-A could
have a role in overall SNARE-mediated fusion events (17).
FFAT motif–containing proteins are characterized by a
short linear motif with the consensus sequence EFFDAxE (i.e.,
two phenylalanines in an acidic tract) (41). These proteins are
implicated in lipid transfer between the ER and other organ-
elles, such as the Golgi apparatus, endosomes, and plasma
Figure 3. Schematic overview of the evolution of proteins containing the VAP domain based on sequence analysis, with emphasis on the three
domain architectures observed in the metazoa. Homology with the prokaryotic PapD cannot be established and is indicated with a question mark. The
VAP-A architecture with the MSP domain, a coiled-coil, and a transmembrane helix can be found throughout eukaryotes and therefore probably dates back
to the last eukaryotic common ancestor (LECA). Many variations on this architecture can be found, including the loss of the coiled-coil region or the C-
terminal transmembrane helix. There are also several gene duplications in the family in the various taxa, such as in plants. Species for which structures have
been determined are named in figure. MSP, major sperm protein.
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membrane (42–44). Interactions with FFAT-containing pro-
teins map to the MSP domain. Accordingly, mutations in the
MSP domain that disrupt FFAT motif binding inhibit VAP-
dependent ER–plasma membrane association (45).
Another FFAT motif–containing protein that interacts with
VAP-B is the tyrosine phosphatase-interacting protein 51
(PTPIP51). Several neuronal functions are regulated by
signaling between mitochondria and the ER. This signaling
involves direct interaction between the two organelles that is
mediated by binding of VAP-B to the outer mitochondrial
membrane protein PTPIP51, as confirmed by independent
biochemical assays (46). VAP-B and PTPIP51 act as inter-
organellar bridges between ER and the mitochondria (46–48).
Both proteins are involved in the regulation of intracellular
Ca2+ homeostasis (48). Accordingly, modulation of VAP-B and
PTPIP51 expression results in variations in ER–mitochondrion
contacts and in Ca2+ exchange between the two organelles.
VAP-B–PTPIP51 tethers also regulate autophagy through
mediating Ca2+ delivery from the ER to mitochondria (49).
Interestingly, proteins of the MOSPD family (MOSPD1, 2,
and 3), which share with VAP-A/B a similar architecture, are
also intraorganelle tethers but with high partner specificity.
MOSPD1 and MOSPD3 prefer unconventional FFAT-related
FFNT (two phenylalanines [FF] in a neutral tract) (50) mo-
tifs. VAPA/VAPB/MOSPD2 and MOSPD1/MOSPD3
assemble into two different ER-attached complexes in control
of interactions between intracellular compartments.
Although quite different among each other, these in-
teractions confirm an important role of VAPs in organelle
tethering and lipid metabolism. In addition to these in-
teractions, the MSP domain of VAP-B was found as a cleavage
product to serve as a ligand of Eph receptors (51). Secreted
MSP domains usually bind to the extracellular signal domains
of these receptor tyrosine kinases and sit on the cell surface.
VAPs in infectious diseases
Interactions of VAPs with various viral nonstructural pro-
teins (nsps) have been conclusively demonstrated (52–54).
Both VAP-A and VAP-B enhance the replication of various
RNA viruses, including murine norovirus, hepatitis C virus
(HCV), rhinovirus, and tombusvirus (Table 2). In many cases,
the viral proteins mimic cellular proteins that normally
interact with VAPs. VAP-A, for instance, binds through
conserved residues in the MSP domain, a conserved motif in
the NS1 domain of the alternative nsp1/2 protein from murine
norovirus, a leading cause of gastroenteritis (55). The residues
of nsp1/2 interacting with VAP-A include the acidic residues
E40, E42, D43, E44, E52, and E54 and the bulky aromatic Y47.
This stretch faithfully mimics the classical FFAT motif in
which aromatic residues are flanked by acidic ones.
Both VAPs bind the nsps NS5A and NS5B of HCV playing
an essential role as host factors for viral replication. NS5A/B
are RNA-dependent RNA polymerase phosphoenzymes that
appear to possess multiple and diverse functions in viral
replication, interferon resistance, and pathogenesis. They have
an N-terminal catalytic domain connected to a membrane-
binding region by an autoregulatory C-linker. It is this linker
that binds the VAP MSP domain. Although the details of how
the interaction works are still unknown, it was shown that
overexpression of VAP-B enhances viral RNA replication
(56, 57). Conversely, disruption through mutation or down-
regulation of VAP-A and VAP-B, but not VAP-C, inhibits viral
replication (58).
By a combined proteomics/genomics analysis, it was also
found that the VAPs have strong interactions with the viral
nsp3/4A protease through nsp4A, which may interfere with
the unfolded protein response machine, preventing host cells
from detecting and degrading viral proteins at the ER (59).
Other interactions with proteins involved in viral replication
comprise proteins implicated in the metabolism of sterol
because this is a major component of the cellular membranes
where viruses assemble viral replicase complexes. Examples of
these interacting proteins are oxysterol-binding protein 1 that
is a component of the cycle fueled by cholesterol-driving hu-
man rhinovirus replication (60, 61) and various oxysterol-
binding protein–related proteins involved in the replication
of the RNA tombusviruses in plants (62).
VAPs play a role also in bacterial infection as, for instance,
Chlamydia trachomatis, an obligate intracellular human
pathogen responsible for ocular and genital infections. The
mechanism involves lipid metabolism and interaction with a
vesicular compartment in the host cell membrane known as an
inclusion, required for the reproductive cycle of the bacterium.
Inclusion of C. trachomatis relies on a set of effector proteins
that are injected into the host cells or inserted into the in-
clusion membrane. Interactions of the bacterial proteins with
host VAP-B enhance lipid import into the bacterial inclusion.
It was proposed that insertion of the C. trachomatis effector
protein IncD in the inclusion membrane contributes to the
recruitment of VAP-B, the lipid transfer ceramide transfer
protein CERT, and the sphingomyelin synthases, SMS1 and
SMS2 (63–65). Together, the complex of these proteins es-
tablishes an on-site sphingomyelin biosynthetic factory critical
for replication in which CERT converts ceramide into sphin-
gomyelin (65).
Table 2
Summary of some of the best described interactions involving VAP-B
Region involved Protein partner Disease associated References
N.D.a CERT Chlamydia infections (63, 64)
MSP domain NS5A Hepatitis C (56)
MSP domain NS5B Hepatitis C (57)
N.D. NS3/4A (NS4A) Hepatitis C (59)




Hepatitis C (51, 56, 57)
MSP domain ATF6 Hepatitis C, ALS8 (76)
MSP domain NS1/2 Diarrheab (55)
N.D. OSBP1 Common coldc (60)
N.D. PTPIP51 AD, PD, FTD, ALSd (46)
MSP domain α-Synuclein PDd (47, 71)
MSP domain p97–FAF1 complex ALS8 (88)
MSP domain ASNA1–TRC complex ALS8 (88)
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal
dementia; MSP, major sperm protein; PD, Parkinson’s disease.
a Not determined.
b Caused by norovirus infection.
c Caused by rhinovirus infection.
d These pathologies are associated with tethering disruption.
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This evidence confirms an active involvement of VAPs in
bacterial and viral infectivity.
VAPs in neurodegenerative diseases
VAP-B has been connected to various neurodegenerative
diseases, including ALS, frontotemporal dementia, AD, and
PD through disruption of mechanisms regulating the ER–
mitochondria tethering (46, 66, 67). In particular, association
with ALS was observed and closely studied in animal models
(68). The RNA-binding proteins fused in sarcoma/translocated
in liposarcoma protein (FUS) (69) and transactive response
DNA binding protein 43 kDa (TDP-43) (67, 70), and both WT
and mutant α-synuclein (47, 71) are for instance known to
disrupt the VAP-B-PTPIP51 interaction with consequent
loosening of the ER–mitochondria interaction, which induces
autophagosome formation. As a consequence, Ca2+ uptake by
mitochondria is perturbed and mitochondrial ATP production
is impaired. Results of coimmunoprecipitation and pull-down
assays argue against a direct interaction between VAP-B and
TDP-43 or FUS. The link seems mediated by GSK3β: several
groups have reported that, in disease states, both TDP-43 and
FUS may activate GSK3β to inhibit binding of VAP-B to
PTPIP51 and reduce the ER–mitochondria connections (69,
70) (Fig. 4). GSK3β is strongly implicated also in AD and PD as
a regulator of the VAP-B–PTPIP51 interaction (70). Regula-
tion might require phosphorylation of PTPIP51 and/or VAP-
B, resulting in inhibition of the GSK3β interaction (70, 71).
α-Synuclein binds instead to the VAP-B MSP domain directly
and disrupts the VAP-B–PTPIP51 interaction (71). Accord-
ingly, overexpression of WT α-synuclein and its PD-related
mutant disrupts the VAP-B–PTPIP51 tether.
Overall, these studies strongly support a direct link
between the VAPs, the VAP-B–PTPIP51 tether, and
neurodegeneration.
The effect of ALS-related clinical mutations on the VAP
fold
Several mutations of VAP-B have been observed in patients
with ALS: P56S, T46I, del160, D130E, A145V, S160Δ, and
V234I (72–75). Among them, the first two are in the MSP
domain, two involve truncations or deletions of the protein,
affecting function, two are in the coiled-coil region, and one
more in the membrane-binding domain. Only the effects of
P26S and T46I mutations have been studied in sufficient detail.
The effects of P56S and T46I on the VAP-B structure were
more closely monitored (Fig. 5, Supplemental Data S3). The
P56S variant is by far the most prevalent form that cose-
gregates with disease in patients with ALS (76). Over-
expression of the P56S mutant of VAP-B leads to
misregulation of ER stress regulatory pathways, inducing ag-
gregation and mislocalization of the protein in non-ER regions
(51, 77). It was demonstrated that mislocalization of the pro-
tein resulted in potentiation of TDP-43–induced motor
neuronal cell death, at variance with WT VAP-B that inhibited
it (78).
The P56S mutation was subjected to a detailed structural
investigation and a close comparison with the WT using
recombinantly produced proteins expressed in bacteria (29).
Isolated WT VAP-B MSP domain was demonstrated to be
well-folded and able to bind to FFAT motifs at a neutral pH.
Acidification of the solution induced reversible unfolding as it
is common to several other well-behaved proteins. Conversely,
the recombinant P56S mutant was proven to be unfolded
already at neutral pH. This behavior can be rationalized by
bearing in mind that P56 is crucially involved in the formation
of the S-shaped conformation of the bulge that allows
switching of the C’ strand between the two sheets. By analogy,
independent mutation of P12 located in the other S-shaped
loop of the MSP domain produced a highly insoluble and
Figure 4. VAP-B tether between the ER and mitochondria and its link to neurodegeneration. VAP-B and PTPIP51 are normally linked together with
interactions between VAP-B and a complementary region of PTPIP51. TDP-43 and fused in sarcoma/translocated in liposarcoma protein may activate GSK3β
that, in turn, inhibits binding of VAP-B to PTPIP51 and reduce the ER–mitochondria connections. This is thought to cause dysregulation and disease. ER,
endoplasmic reticulum.
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unfolded protein. This study thus strongly suggested that the
P56S mutation causes a crucial destabilization of the MSP
native structure, with consequent aggregation of the protein
and loss of function.
Unlike P56S, T46I was shown not to lead to complete
disruption of the native fold of the protein but to reduce
appreciably its thermodynamic stability and unfolding cooper-
ativity (79). The key to understanding the causes of this desta-
bilization is to consider that T46 is a partially buried residue in
the available structure of Vap-B (3ikk) and creates a pocket in
the MSP fold. Substitution of a small buried semihydrophilic
residue by a bulky hydrophobic isoleucine is more than likely to
destabilize the fold causing misfolding and aggregation.
Accordingly, studies of the interactome of the mutant have
resulted in loss or loosening of some interactions (79).
Altogether, these results provide models to explain the
mechanism for the role of ALS-related mutations in the
pathology.
A relationship between ALS and viral infection
We have described the role of VAPs both in infective and
neurodegenerative diseases. Do these events occur through
independent mechanisms? Probably not: increasing evidence
supports a relationship between disregulation of the gut
microbiota with the risk of neurodegeneration through alter-
ation of circulating levels of inflammatory cytokines and/or
production of neurotoxins that would affect the central ner-
vous system, as observed in PD, AD, and other disorders (80).
Independent studies have, for instance, detected differences in
the bacterial taxa of patients with PD as compared with healthy
controls (81). First linked to herpes simplex virus in early
pioneering studies (82), it has been more recently suggested
that AD may be linked to an imbalance of the gut microbiota
through what is called the gut–brain axis (83).
A pathogenic connection between ALS and retroviruses was
suggested by the observation of HIV cases associated with ALS
or ALS-like diseases (4–7). Accordingly, a recent report dis-
closed that a patient with chronic HCV developed an ALS-like
syndrome (8). Reverse transcriptase, the enzyme utilized by
retroviruses to replicate, has been detected in a significantly
higher percent of patients with sporadic ALS than healthy
controls (84, 85). Postmortem analysis of brain tissues of pa-
tients with ALS has also revealed a significantly higher
expression of human endogenous retrovirus K (86). Interest-
ingly, antiviral therapies seem to improve ALS-like symptoms
in some individuals (87). It is thus not inconceivable to explore
whether this link could involve VAP-mediated processes, given
the role that these proteins play in several essential cellular
functions.
The ways this link could be realized are multifold. Mis-
regulation of the ER stress regulatory pathways seems to be at
the root of both the pathological mechanism for ALS and of
HCV infection (76). Viral NS5A, FFAT-containing proteins,
and the EphA4 receptor bind, for instance, overlapping sur-
faces on the MSP domain and have been shown to compete for
binding (56). In some patients with HCV, the NS5A protein
has been found to accumulate abnormally with consequent
potential perturbation of the physiological function of the
VAPs in a manner similar to that induced by the T46I muta-
tion. The hypothesis is supported by the fact that the two
residues affected by the ALS-causing mutations P56 and T46
are both located at the interaction surface of MSP with NS5A
(56). Some authors have suggested that HCV infection might
not only induce an ALS-like syndrome but also trigger path-
ogenesis associated with signaling pathways mediated by
EphA2 and EphA5 (57). Eph receptors and their ephrin ligands
are polymorphic families of cell–surface signaling molecules
important in many aspects of development, including cell
differentiation and spatial organization of growing tissues.
Dysfunction of ephrin signaling is implicated in several path-
ological conditions including but not limited to cancer.
The evidence presented could thus explain a VAP-mediated
link between infectious and neurodegenerative diseases.
Conclusions
In this review, we have analyzed the structure and functions
of proteins from the VAP family, an important tethering
component of the eukaryotic cell. We have discussed how the
Ig fold of the conserved globular MSP domain differs from
more canonical Ig fold types and shares similarity with two
other protein families, nematode MSP and bacterial PapD.
Although in different ways, all three protein families seem to
be implicated in functions that would require specific me-
chanical properties which might be encoded in the S-type fold.
Detailed sequence and structural comparison would suggest
that only the MSP family is evolutionarily related to VAPs.
We have then discussed the wide interactome of VAPs and
how they interact both with endogenous and viral proteins
often with overlapping regions, suggesting competition among
these interactions. Clear links seem also to associate VAPs and
specifically VAP-B with neurodegenerative diseases, such as
ALS. Altogether, our review demonstrates how the VAP family
has an important role in the healthy metabolism and how
Figure 5. Mapping ALS-related mutations onto the structure of the MSP
domain of VAP-B (PDB code: 3ikk). The backbone of the protein is shown
as a ribbon in stereo. The adopted view differs from that of Figure 1 by a
rotation of 90 degrees around an axis on the page. The side chains of T46
and P56 are shown. T46 has an accessible surface area of 31 Å2 and is thus
semiexposed. P56 is also semiexposed (48 Å2) and is key in defining the
switching point of strand C’. ALS, amyotrophic lateral sclerosis; MSP, major
sperm protein; PDB, Protein Data Bank.
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destabilization of the structure and/or interactions leads to
pathology. Much more work remains to be done to solve the
structures at atomic resolution of the several complexes
involving the VAPs, which will constitute an essential step to
understand their functions.
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